外科理论与实践 ›› 2018, Vol. 23 ›› Issue (01): 87-90.doi: 10.16139/j.1007-9610.2018.01.021
Maneesh K. Beeharry 综述, 刘文韬, 燕敏 审校
收稿日期:2017-04-14
出版日期:2018-01-25
发布日期:2020-07-25
通讯作者:
燕敏,E-mail: ym10299@163.com
Received:2017-04-14
Online:2018-01-25
Published:2020-07-25
中图分类号:
Maneesh K. Beeharry, 刘文韬, 燕敏. 胃癌根治术联合腹腔内温热灌注化疗的有效性和安全性[J]. 外科理论与实践, 2018, 23(01): 87-90.
| [1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132. [2] Chen W, Zheng R, Zuo T, et al.National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res,2016,28(1):1-11. [3] Yu W, Whang I, Chung HY, et al.Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial[J]. World J Surg,2001,25(8):985-990. [4] Fujimoto S, Takahashi M, Mutou T, et al.Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery[J]. Cancer,1997, 79(5):884-891. [5] Hirose K, Katayama K, Iida A, et al.Efficacy of conti-nuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis[J]. Oncology,1999,57(2):106-114. [6] Yonemura Y, Kawamura T, Bandou E, et al.Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion[J]. Br J Surg,2005,92(3):370-375. [7] Glehen O, Schreiber V, Cotte E, et al.Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer[J]. Arch Surg,2004,139(1):20-26. [8] Li C, Yan M, Chen J, et al.Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination[J]. J Surg Oncol,2010,102(5):361-365. [9] Gill RS, Al-Adra DP, Nagendran J, et al.Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity[J]. J Surg Oncol,2011, 104(6):692-698. [10] Yang XJ, Huang CQ, Suo T, et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol,2011,18(6):1575-1581. [11] Yuan M, Wang Z, Hu G, et al.A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Mol Clin Oncol,2016, 5(2):395-399. [12] Facchiano E, Risio D, Kianmanesh R, et al.Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature[J]. Ann Surg Oncol,2012,19(9):2946-2950. [13] Randle RW, Swett KR, Swords DS, et al.Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites[J]. Ann Surg Oncol,2014,21(5):1474-1479. [14] Roviello F, Caruso S, Neri A, et al.Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale[J]. Eur J Surg Oncol,2013,39(12):1309-1316. [15] Seshadri RA, Glehen O.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer[J]. World J Gastroenterol,2016,22(3):1114-1130. [16] Polom K, Marano L, Roviello G, et al.Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence[J]. Int J Hyperthermia,2016,32(2):173-179. [17] Zhu ZG, Tang R, Yan M, et al.Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study[J]. Dig Surg,2006,23(1-2):93-102. [18] Sun J, Song Y, Wang Z, et al.Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the rando-mized controlled trials[J]. BMC Cancer,2012,12:526. [19] Mi DH, Li Z, Yang KH, et al.Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials[J]. Int J Hyperthermia,2013,29(2):156-167. [20] Coccolini F, Cotte E, Glehen O, et al.Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials[J]. Eur J Surg Oncol,2014,40(1):12-26. [21] 倪震天, 李琛, 严超, 等. 手术联合术中腹腔温热化疗治疗进展期胃癌的疗效及安全性的Meta分析[J]. 中华胃肠外科杂志,2016,19(12):1406-1413. [22] Fujimura T, Yonemura Y, Nakagawara H, et al.Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer[J]. Oncol Rep,2000,7(4):809-814. [23] Rudloff U, Langan RC, Mullinax JE, et al.Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial[J]. J Surg Oncol,2014,110(3):275-284. [24] Mohamed F, Moran BJ.Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve[J]. Cancer J,2009,15(3):196-199. [25] Pascual-Ramírez J, Sánchez García S, González Ruiz de la Herrán F, et al. Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs[J]. Arch Gynecol Obstet,2014,290(1):121-129. [26] Raspe C, Piso P, Wiesenack C, et al.Anesthetic management in patients undergoing hyperthermic chemotherapy[J]. Curr Opin Anaesthesiol,2012,25(3):348-355. [27] Morris DL, Chambers HF, Morris MG, et al.Hemodynamic characteristics of patients with hypothermia due to occult infection and other causes[J]. Ann Intern Med,1985,102(2):153-157. [28] Passot G, Bakrin N, Isaac S, et al.Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies[J]. Eur J Surg Oncol,2014,40(8):957-962. [29] Putzu M, Casati A, Berti M, et al.Clinical complications, monitoring and management of perioperative mild hypothermia: anesthesiological features[J]. Acta Biomed,2007,78(3):163-169. [30] Scott EM, Buckland R. A systematic review of intraoperative warming to prevent postoperative complications[J]. AORN J,2006,83(5):1090-1104, 1107-1113. [31] Stuart OA, Stephens AD, Welch L, et al.Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C[J]. Ann Surg Oncol,2002,9(2):186-191. [32] Schmid K, Boettcher MI, Pelz JO, et al.Investigations on safety of hyperthermic intraoperative intraperitoneal chemo-therapy (HIPEC) with Mitomycin C[J]. Eur J Surg Oncol,2006,32(10):1222-1225. [33] Guerbet M, Goullé JP, Lubrano J.Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)[J]. Eur J Surg Oncol,2007,33(5):623-626. [34] Konate A, Poupon J, Villa A, et al.Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure[J]. J Surg Oncol,2011,103(1):6-9. [35] Bharali DJ, Mousa SA.Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise[J]. Pharmacol Ther,2010, 128(2):324-335. [36] Matano D, Moriwaki T, Tange Y, et al.Successful long-term management with a single administration of tri-weekly nab-paclitaxel in a patient with advanced gastric cancer with peritoneal dissemination[J]. Intern Med,2017, 56(8):921-923. [37] Frank D, Tyagi C, Tomar L, et al.Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors[J]. Int J Nanomedicine,2014,9:589-613. [38] Wong BS, Yoong SL, Jagusiak A, et al.Carbon nanotubes for delivery of small molecule drugs[J]. Adv Drug Deliv Rev,2013,65(15):1964-2015. |
| [1] | 戴志强, 郑金鑫, 唐兆庆, 张启, 顾远, 史忠义, 胡国华, 孙益红. 淋巴结转移率对Ⅱ~Ⅲ期胃癌根治术后病人预后的评估[J]. 外科理论与实践, 2022, 27(05): 429-434. |
| [2] | 李娜娜, 齐涛, 朱黎明. 血清胃蛋白酶原、胃泌素17和幽门螺杆菌IgG抗体在胃部疾病初筛中的临床价值[J]. 诊断学理论与实践, 2022, 21(04): 509-513. |
| [3] | 鲍萍萍, 吴春晓, 顾凯, 庞怡, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 吴梦吟, 付晨, 施燕. 上海市2016年胃癌发病特征及2002年至2016年胃癌发病趋势分析[J]. 诊断学理论与实践, 2022, 21(04): 462-469. |
| [4] | 赵丽琴, 郭伟剑, 余诺亚, 吴珺玮, 张俊. 激活素A对胃癌细胞迁移和有氧糖酵解的影响[J]. 内科理论与实践, 2022, 17(04): 317-323. |
| [5] | 聂明明, 朱正纲. 腹腔镜探查对进展期胃癌精准分期的临床意义[J]. 外科理论与实践, 2022, 27(04): 365-370. |
| [6] | 郭良奇, 严志龙, 张谋成. 腹腔镜经胃腔手术治疗胃黏膜下肿瘤和早期胃癌[J]. 外科理论与实践, 2022, 27(04): 380-383. |
| [7] | 陆伟辉, 刘威, 王聪, 王正林. CXCR2对胃癌细胞侵袭、迁移及凋亡的影响[J]. 外科理论与实践, 2021, 26(5): 430-436. |
| [8] | 朱正纲. 预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(01): 1-6. |
| [9] | 姬忠贺, 李雁. 肿瘤细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移的现状与前景[J]. 外科理论与实践, 2021, 26(01): 11-16. |
| [10] | 陈小龙, 胡建昆. 腹腔镜探查胃癌腹膜转移的临床意义[J]. 外科理论与实践, 2021, 26(01): 17-20. |
| [11] | 张景辉, 徐袁, 印慨. 胃癌腹膜转移的诊断和相关治疗[J]. 外科理论与实践, 2021, 26(01): 28-33. |
| [12] | 严超, 燕敏, 朱正纲. 新辅助腹腔内联合全身化疗应用于胃癌腹膜转移的临床价值和实施要点[J]. 外科理论与实践, 2021, 26(01): 38-40. |
| [13] | 杨中印, 李琛, 刘文韬, 施敏, 吴珺玮, 郑亚南, 朱正伦, 华子辰, 倪震天, 陆晟, 燕敏, 严超, 朱正纲. 胃癌腹膜转移病人腹腔化疗港并发症发生及危险因素分析[J]. 外科理论与实践, 2021, 26(01): 41-47. |
| [14] | 刘轩宇, 陈磊. 外泌体在胃癌腹膜转移中机制的研究进展[J]. 外科理论与实践, 2021, 26(01): 76-78. |
| [15] | 蔡业冰, 陈拥军. 胆囊癌伴脐部转移（附1例报告）[J]. 外科理论与实践, 2020, 25(06): 520-522. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
